Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Akt inhibitor MK2206 in advanced breast cancer has completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Carcinoma
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• MK2206 (MK2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Breast Carcinoma, Stage IIIB Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-12